Compare ONDS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | CRSP |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.2B |
| IPO Year | 2015 | 2016 |
| Metric | ONDS | CRSP |
|---|---|---|
| Price | $6.19 | $51.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 23 |
| Target Price | $18.88 | ★ $85.63 |
| AVG Volume (30 Days) | ★ 49.9M | 1.7M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $50,731,000.00 | ★ $289,590,000.00 |
| Revenue This Year | $957.99 | $1,052.09 |
| Revenue Next Year | $88.66 | $273.88 |
| P/E Ratio | $16.18 | ★ N/A |
| Revenue Growth | 605.31 | ★ 9169.85 |
| 52 Week Low | $4.95 | $44.12 |
| 52 Week High | $15.28 | $75.06 |
| Indicator | ONDS | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 30.14 | 43.58 |
| Support Level | N/A | $50.19 |
| Resistance Level | $7.98 | $60.71 |
| Average True Range (ATR) | 0.34 | 2.58 |
| MACD | -0.10 | -0.50 |
| Stochastic Oscillator | 19.81 | 20.43 |
Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.